Bioethical considerations of monoclonal B‐cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation
Year: 2007
Type: article
Abstract: Monoclonal B-cell lymphocytosis (MBL) is a recently described laboratory finding in otherwise healthy individuals. In MBL, a light chain-restricted, clonal B-cell population, often with a chronic lymphocytic leukaemia (CLL) phenotype, is identified by flow cytometry. Although the prognostic significance remains unclear, there is an increased incidence in ageing populations and those with a family history of CLL. During the past decade of MBL study, three families have come to our attention in which prospective sibling haematopoietic stem cell donors were found to have an MBL. These families raise complex bioethical issues with regard to disclosure of research data, eligibility for clinical trials and potential donor transfer of MBL. These issues are explored in this report. Identification of MBL among prospective sibling transplant donors will become a common occurrence in transplant practice as transplantation is increasingly offered to older individuals and those with CLL.
Source: British Journal of Haematology
Institutions: National Institutes of Health, National Cancer Institute, National Cancer Institute, Center for Cancer Research, National Institutes of Health Clinical Center, Emory University, Winship Cancer Institute, Westat (United States), Division of Cancer Epidemiology and Genetics, Center for Biologics Evaluation and Research, United States Food and Drug Administration
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1996590294
